Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Centricity Research

Neither a doctor nor a teaching hospital

Research payments

$1,532,743

634 payments

Through program year 2025, Centricity Research is reported as receiving $1,532,743 in research payments, across 634 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $745,276 347
2024 Research $576,040 220
2023 Research $161,108 49
2022 Research $50,318 18

Breakdown

Who paid Research payments · program years 2022–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $601,232 76 payments
  2. Boehringer Ingelheim International GmbH $272,210 221 payments
  3. Novo Nordisk AS $156,263 207 payments
  4. Novartis Pharmaceuticals Corporation $107,111 4 payments
  5. Amgen Inc. $82,727 5 payments
  6. AstraZeneca UK Limited $79,753 6 payments
  7. Seqirus USA Inc $75,005 41 payments
  8. AstraZeneca Pharmaceuticals LP $55,031 24 payments
  9. Biogen, Inc. $39,698 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $34,246 25 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $324,837 151 payments
  2. Obesity Long term safety in patients with CV risk $264,050 16 payments
  3. MRD/PoCP study in NFLD (12 wks) $157,333 2 payments
  4. Nn9536-7752 $113,062 182 payments
  5. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $97,389 2 payments
  6. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $72,764 37 payments
  7. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $63,563 3 payments
  8. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $39,180 3 payments
  9. Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis $35,923 100 payments
  10. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $32,780 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record